The global “diabesity” market is swelling into a once‑in‑a‑generation opportunity, and Eli Lilly, Novo Nordisk—and now a new class of device innovators like Modular Medical (NASDAQ: MODD)—are still lacing up their running shoes rather than sprinting for the finish line. For investors, the race is early, the field is widening, and the catalysts lining the track look more durable than the latest diet fad.
Diabesity: A Mega-Trend With Staying Power
The fusion of diabetes and obesity into the so‑called diabesity epidemic has created a treatment market that could reach around $100 billion by 2030, with some forecasts stretching to $150 billion by 2035 as pricing pressure is offset by massive volume growth. GLP‑1–based medicines, originally developed for type 2 diabetes, are now the backbone of this market thanks to their dual ability to control blood sugar and drive meaningful weight loss.
Analysts increasingly see “diabesity” as a secular, not cyclical, growth theme, with payers recognizing that spending today on GLP‑1 therapies may reduce tomorrow’s costly cardiovascular, renal, and orthopedic complications. Insurance coverage for GLP‑1 drugs in diabetes is expected to stay robust at roughly 70% in 2026 and could rise toward 75% in 2027, reinforcing the notion that these medicines are shifting from luxury add‑ons to standard of care.
Lilly and Novo: From Niche to National Pastime
Eli Lilly and Novo Nordisk have moved from specialist pharma names to household tickers, riding unprecedented demand for their GLP‑1 franchises. Lilly’s cardiometabolic health division, which includes Mounjaro for diabetes and Zepbound for obesity, has already become the company’s growth engine, with that segment approaching roughly $40 billion in revenue and representing the majority of its sales. Novo’s diabetes and obesity division is even more concentrated, accounting for over 90% of its business, reflecting a pure‑play exposure to this therapeutic wave.
The market has rewarded that focus generously: Lilly’s shares have tripled on the strength of its weight‑loss portfolio, and Novo has similarly enjoyed a multi‑year rerating as investors treat these companies less like traditional drug makers and more like long‑duration growth platforms. Yet, as any seasoned investor knows, trees do not grow to the sky—eventually, they start issuing dividends.
The Pill Era: From Needles to Nightstands
If the first chapter of the GLP‑1 story was about injections, 2026 is fast becoming the year of the obesity pill. Novo Nordisk has seized an early advantage with an oral version of Wegovy that quickly ramped to roughly 50,000 prescriptions per week within its first three weeks on the U.S. market, signaling significant latent demand from patients who dislike injections or never saw their weight as “shot‑worthy.”
Lilly is lining up its own oral contender, orforglipron, with analysts expecting regulatory milestones that could narrow Novo’s lead and potentially shift share toward Lilly if efficacy and tolerability mirror its injectable tirzepatide. Goldman Sachs (GS) estimates that pills could capture around a quarter of the global weight‑loss market by 2030—about $22 billion in annual sales—turning the medicine cabinet into prime commercial real estate.
Devices Join the Party: Modular Medical’s “Almost-Pumper” Bet
As GLP‑1 therapies reframe how diabesity is treated, device makers are quietly building the infrastructure to support day‑to‑day insulin management for the millions who still need it. Modular Medical (NASDAQ: MODD) is positioning its Pivot tubeless insulin patch pump squarely at “almost‑pumpers”—adult patients on multiple daily injections who have avoided traditional pumps because they are viewed as complex, cumbersome, or costly.
Pivot is designed as a removable, two‑part, tubeless 3 milliliter patch pump that can be detached for activities like showering and does not require a separate controller for bolusing, with an interface built for simplicity and affordability. Modular Medical estimates that this almost‑pumper segment represents roughly a $3 billion opportunity within a broader insulin pump market of about $8 billion globally, while the global insulin patch pump category alone is expected to grow from just under $1 billion in 2022 to more than $2 billion by 2030 at an annual rate of around 11%.
Pivot’s Timeline and Market Fit
Modular Medical has submitted Pivot for FDA 510(k) clearance and has begun producing validation lots for its tubeless patch pump cartridges, targeting a commercial launch in the first quarter of 2026, subject to regulatory sign‑off. The company recently validated its Pivot controller manufacturing line and raised additional capital to support scale‑up, signaling that it expects to meet high‑volume demand if clearance comes through on time.
The strategy is straightforward: bring an easy‑to‑learn, lower‑cost patch pump to millions of adults who are clinically eligible for pump therapy but have remained on injections, thereby expanding the pump category rather than just trading share with incumbents. In a diabesity world increasingly dominated by GLP‑1 headlines, Pivot serves as a reminder that insulin delivery still matters—and that businesses helping patients bridge the gap between injections and full ecosystem management can carve out attractive niches.
A Market That’s Getting Bigger—and Cheaper
Early hyper‑bullish projections pegged the obesity drug market at up to $150–$200 billion by the early 2030s, but recent estimates have trimmed that outlook to roughly $100 billion by 2030, with the higher targets pushed to mid‑decade as competition and price pressures intensify. Rather than a warning sign, some analysts see falling prices as the classic hallmark of a maturing blockbuster category, enabling broader access and higher overall volumes.
BMO Capital Markets, for example, models GLP‑1s reaching more than $150 billion in annual revenue by 2033, including about $100 billion from obesity alone, with the balance from diabetes indications. TD Cowen notes that those forecasts could prove conservative if direct‑to‑consumer channels and cash‑pay offerings draw in millions of incremental patients beyond the insured core. In Wall Street terms, the pie might get sliced more thinly, but the bakery is expanding.
Catalysts on the Horizon: Beyond the Bathroom Scale
Investors watching Lilly, Novo, and now device names like Modular Medical are focused on several key catalysts that could extend the diabesity rally:
- Broader indications
- Ongoing and planned trials are exploring GLP‑1–based regimens in cardiovascular risk reduction, sleep apnea, liver disease, and kidney protection, opening additional revenue streams on the same molecular backbone.
- Positive outcomes could help cement payer support by demonstrating that these drugs save money elsewhere in the health system.
- Capacity and supply
- Lilly and Novo are investing heavily in manufacturing expansions to ease supply bottlenecks that have periodically constrained growth and fueled gray‑market “copycat” compounding.
- On the device side, Modular Medical’s validation of its Pivot controller and cartridge lines is meant to prove it can scale efficiently into the patch‑pump niche.
- Policy and coverage
- Incremental moves by governments and private insurers to cover obesity medications more broadly, including in employer plans and public programs, could unlock millions of new eligible patients.
- At the same time, expanding reimbursement for wearable insulin patch pumps is fueling growth in a U.S. market expected to reach about $2.8 billion by 2033, with adoption rising in both type 1 and type 2 diabetes.
The Competitive Cast: Not Just a Two-Stock Show
While Lilly and Novo dominate the headlines, they are hardly alone on the diabesity stage. Large‑cap peers such as Amgen (AMGN) are advancing next‑generation obesity candidates, while consumer‑facing platforms like Hims & Hers are eyeing GLP‑1–adjacent offerings aimed at cash‑pay customers. In parallel, Modular Medical (NASDAQ: MODD) and other device makers are targeting specific behavioral and economic barriers that have historically limited pump adoption among adults.
This incoming competition is one reason Street forecasts have become more nuanced, with some models baking in share shifts and faster price erosion even as total prescriptions and device penetration soar. For now, Lilly and Novo are benefiting from first‑mover advantages in efficacy data, brand recognition, and payer relationships, while companies like Modular Medical look to ride the broader tailwind by filling under‑served pockets of demand.
What Could Go Wrong—and Why the Market Still Likes Its Odds
The diabesity trade is not without risks. Safety concerns, such as rare but serious side effects, remain on investor radars and could resurface as drugs penetrate broader, less‑screened populations. Policy shifts, including potential price negotiations or coverage restrictions, could also weigh on margins, especially in the U.S., where list prices have drawn political scrutiny.
On the device side, Modular Medical still needs FDA clearance for Pivot and must prove that its simple, lower‑cost design translates into real‑world adoption and durable reimbursement, not just engineering elegance. Yet current earnings power at Lilly and Novo provides a meaningful cushion, with Lilly guiding 2026 revenue in the $80–$83 billion range and Novo continuing to post double‑digit top‑line growth as Wegovy and Ozempic scale globally. In simple terms, investors are being paid handsomely today to wait for tomorrow’s catalysts.
For Long-Term Investors, a Secular Story in Mid-Course
For long‑horizon investors, the diabesity theme blends three elements that rarely travel together: large, tangible current sales; credible multi‑year pipelines; and a societal problem no one expects to “solve” quickly. Pills, broader indications, smarter devices, and expanding coverage look set to take GLP‑1 treatments and next‑generation insulin delivery from specialty tools to everyday infrastructure in cardiometabolic care, much as statins did for cholesterol a generation ago.
Lilly and Novo may already wear premium valuations, and Modular Medical is still in the pre‑clearance stage, but the underlying market is in the early innings, and the scoreboard keeps adding new lines—obesity, diabetes, cardiovascular risk, liver disease, and technology‑enabled insulin delivery. In a market often obsessed with the next quarter, diabesity is one story where the long run might actually arrive sooner than expected, waistlines, wearables, and portfolios included.
The Sources
[1] Modular Medical Announces Successful Validation of Controller … https://finance.yahoo.com/news/modular-medical-announces-successful-validation-133000518.html
[2] The ‘Diabesity’ Market Is Set to Explode. Lilly and Novo Stocks Face … https://www.barrons.com/articles/diabesity-market-set-to-explode-lilly-and-novo-stock-catalysts-cb11db05
[3] Analysis-Obesity market sales potential tightens as Novo and Lilly … https://finance.yahoo.com/news/analysis-obesity-market-sales-potential-110742804.html
[4] 2026 is the year of obesity pills from Novo Nordisk, Eli Lilly – CNBC https://www.cnbc.com/2026/01/10/2026-is-the-year-of-obesity-pills-from-novo-nordisk-eli-lilly-.html
[5] Obesity market sales potential tightens as Novo and Lilly enter new … https://www.reuters.com/business/healthcare-pharmaceuticals/obesity-market-sales-potential-tightens-novo-lilly-enter-new-era-2026-02-02/
[6] The $190 Billion ‘Diabesity’ Market Is Set to Explode. Lilly and Novo … https://www.moomoo.com/hant/news/post/67994026/the-190-billion-diabesity-market-is-set-to-explode-lilly
[7] Lilly vs. Novo Nordisk: Obesity Drug Giants’ Face-Off in 2026 https://finance.yahoo.com/news/lilly-vs-novo-nordisk-obesity-170000484.html
[8] Eli Lilly gaining in GLP-1 market over Novo Nordisk, earnings show https://www.cnbc.com/2026/02/04/eli-lilly-novo-nordisk-earnings-glp1-market.html
[9] Lilly Shares Have Tripled on Weight-Loss Drugs. Why the Stock … https://www.barrons.com/articles/eli-lilly-stock-price-weight-loss-drugs-ec064ec5
[10] Modular Medical hits validation milestone for insulin patch pump https://www.drugdeliverybusiness.com/modular-medical-validation-milestone-pivot/
[11] Modular Medical Achieves Key Manufacturing Milestone for Pivot … https://www.biospace.com/press-releases/modular-medical-achieves-key-manufacturing-milestone-for-pivot-tubeless-insulin-patch-pump
[12] Insulin Patch Pumps Market Size And Share Report, 2030 https://www.grandviewresearch.com/industry-analysis/insulin-patch-pump-market
[13] Latest MODD News – Modular Medical Announces 1-for-30 Reverse … https://www.stocktitan.net/news/MODD/
[14] Modular Medical Submits Pivot Tubeless Insulin Patch Pump for … https://finance.yahoo.com/news/modular-medical-submits-pivot-tubeless-140000932.html
[15] Modular Medical prices $12M public offering to support insulin pump https://www.drugdeliverybusiness.com/modular-medical-prices-12m-public-offering/
[16] Modular Medical validates Pivot controller line for Q1 2026 launch https://www.investing.com/news/company-news/modular-medical-validates-pivot-controller-line-for-q1-2026-launch-93CH-4327291
[17] Modular Medical Announces $12.0 Million Public Offering Priced at … https://www.newswire.com/news/modular-medical-announces-12-0-million-public-offering-priced-at-a-premium-to
[18] Modular Medical Says its Patch Pump Is Close to Commercial Launch https://www.diabetech.info/p/modular-medical-announces-it-s-insulin-pump-is-close-to-commercial-launch
[19] Outlook for Obesity in 2026: From Consolidation to Acceleration https://www.iqvia.com/locations/emea/blogs/2026/01/outlook-for-obesity-in-2026
[20] Eli Lilly, Novo Nordisk report strong earnings as GLP-1 race heats up https://www.healthcare-brew.com/stories/2025/05/08/eli-lilly-novo-nordisk-strong-earnings-glp-1
[21] US Wearable Insulin Patch Pump Market: Unveiling Competitive … https://www.linkedin.com/pulse/us-wearable-insulin-patch-pump-market-unveiling-6jfpf
[22] United States Wearable Insulin Patch Pump Market Size, Brands … https://www.linkedin.com/pulse/united-states-wearable-insulin-patch-pump-market-zqjvf
[23] The $190 Billion ‘Diabesity’ Market Is Set to Explode. Lilly and Novo … https://www.moomoo.com/news/post/67994026/the-190-billion-diabesity-market-is-set-to-explode-lilly
[24] Modular Medical (MODD) Stock Price & Overview https://stockanalysis.com/stocks/modd/
[25] Investor Relations – Modular Medical https://ir.modular-medical.com/press-release-details.php?newsId=c03c9a99-1d99-480e-b130-1843d0c71435
[26] Modular Medical Advances Pivot Tubeless Patch Pump Toward FDA … https://www.towardshealthcare.com/news/modular-medical-pivot-patch-pump
